RNS Number : 2334J

Oxford Biomedica PLC

01 April 2015

For filings with the FCA include the annex
For filings with issuer exclude the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii				Oxford BioMedica plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights					√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii		Aviva plc & its subsidiaries
4. Full name of shareholder(s)  (if different from 3.):iv		Registered Holder: BNY Norwich Union Nominees Limited    7,731,682*    Chase (GA Group) Nominees Limited    197,907,307* *denotes direct interest   Chase (GA Group) Nominees Limited      16,452,188 Chase Nominees Limited                            6,527,175 Vidacos Nominees Limited                         1,471,192
5. Date of the transaction and date on which the threshold is crossed or reached: v		31 March 2015
6. Date on which issuer notified:		1 April 2015
7. Threshold(s) that is/are crossed or reached: vi, vii		7% to 8% Change at Direct Interest Level

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction				Resulting situation after the triggering transaction
	Number of Shares		Number of Voting Rights		Number of shares		Number of voting rights		% of  voting rights x
					Direct		Direct xi	Indirect xii	Direct		Indirect
Ordinary Shares GB00066458157	240,000,000		240,000,000		250,089,544		205,638,989	44,450,555	8.01%		1.73%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument		Expiration date xiii		Exercise/ Conversion Period xiv		Number of voting rights that may be acquired if the instrument is exercised/ converted.				% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date xvii	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	% of voting rights xix, xx
					Nominal	Delta
					Total (A+B+C)
Number of voting rights				Percentage of voting rights
250,089,544				9.74%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: ·      Aviva plc (Parent Company) ·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
10. Name of the proxy holder:		See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:	Figures are based on a total number of voting rights of 2,567,098,228 as per the Company's Total Voting Rights Announcement of 3 March 2015.
14. Contact name:	Tim Watts, Chief Financial Officer, Oxford BioMedica
15. Contact telephone number:	+44 (0) 1865 783 000

This information is provided by RNS

The company news service from the London Stock Exchange

END HOLUAOVRVWASRAR